Abstract
Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. 1496.
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Carcinoma, Transitional Cell*
-
Cell Adhesion Molecules / genetics
-
Cell Adhesion Molecules / metabolism
-
Humans
-
Nectins
-
Urinary Bladder Neoplasms* / drug therapy
-
Urinary Bladder Neoplasms* / genetics
-
Urinary Bladder Neoplasms* / pathology
Substances
-
enfortumab vedotin
-
Nectins
-
Antibodies, Monoclonal
-
Cell Adhesion Molecules